-
公开(公告)号：EP2797621B1
公开(公告)日：2019-03-06
申请号：EP12861579.6
申请日：2012-12-28
发明人： KIM, Seung Su , LIM, Se Young , JUNG, Sung Youb , KWON, Se Chang
-
公开(公告)号：EP2753348B1
公开(公告)日：2019-12-11
申请号：EP12830783.2
申请日：2012-09-05
-
3.发明公开PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE 审中-公开药物组合物进行预防和治疗非酒精性脂肪肝病
公开(公告)号：EP2838549A1
公开(公告)日：2015-02-25
申请号：EP13757286.3
申请日：2013-03-08
CPC分类号： A61K47/48215 , A61K38/26 , A61K39/3955 , A61K47/60 , A61K47/6883 , A61K2039/505 , C07K14/605 , C07K16/18 , C07K2317/41 , C07K2317/75 , C07K2317/94
摘要： The present invention relates to a pharmaceutical composition for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD), including a conjugate prepared by covalently linking an insulinotropic peptide, a non-peptidyl polymer and an immunoglobulin Fc region. The composition of the present invention maintains the in-vivo activity of the peptide at a relatively high level, and remarkably increases the blood half-life, thereby preventing triglyceride accumulation which is a typical feature of non-alcoholic fatty liver disease. Ultimately, it can be desirably employed for the prevention and treatment of non-alcoholic fatty liver disease.
-
公开(公告)号：EP2797621A1
公开(公告)日：2014-11-05
申请号：EP12861579.6
申请日：2012-12-28
发明人： KIM, Seung Su , LIM, Se Young , JUNG, Sung Youb , KWON, Se Chang
CPC分类号： A61K47/48415 , A61K38/26 , A61K47/60 , A61K47/68 , A61K47/6811
摘要： Provided are a glucagon-like peptide-2 (GLP-2) conjugate containing native GLP-2 or its derivative and an immunoglobulin Fc fragment being covalently linked via a non-peptidyl polymer, wherein the native GLP-2 or its derivative has a thiol group introduced at its C-terminal end, and one end of the non-peptidyl polymer is linked to an amino acid residue of the GLP-2 other than the N-terminal amino group thereof; a method for preparing the GLP-2 conjugate; a pharmaceutical composition comprising the same; and a method for treating or preventing intestinal disease, intestinal injury, or gastrosis by using the same. Since the GLP-2 conjugate of the present invention has a remarkably increased binding affinity to a GLP-2 receptor, it shows a prolonged in vivo half-life and an improved in vivo durability and stability.
-
5.发明公开A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING INTERFERON ALPHA CONJUGATE 有权药物组合物，癌的干扰素α缀合物的治疗
公开(公告)号：EP2753348A1
公开(公告)日：2014-07-16
申请号：EP12830783.2
申请日：2012-09-05
发明人： JUNG, Sung Youb , WOO, Young Eun , LIM, Se Young , CHOI, In Young , LEE, Jae Ho , KWON, Se Chang , MOON, Sung Hwan , LIU, Jiawang
IPC分类号： A61K38/21 , A61K39/395 , A61K47/48 , A61K47/30 , A61P35/00
摘要： A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency. Co-administration of an anti-cancer agent and the interferon alpha conjugate having excellent anti-cancer activity reduces administration dose of anti-cancer agent so as to reduce side effects of anti-cancer agent and increase treatment compliance of patient.
-
-
-
-
搜索结果
5 条记录 (耗时 0.01 秒)
